단클론항체 치료제 시장 : 항체 유형, 적응증, 분자 표적, 제조 기술, 투여 경로, 치료법, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Monoclonal Antibody Therapeutics Market is projected to grow by USD 672.50 billion at a CAGR of 13.71% by 2032.

Monoclonal antibody therapeutics remain one of the most clinically validated and commercially important classes in biologic medicines, with established use across oncology, autoimmune disorders, inflammatory diseases, infectious disease prevention, ophthalmology, neurology, and transplant medicine. Their strategic strength is supported by decades of regulatory experience, expanding indication coverage, and the proven ability of antibodies to bind disease-relevant targets with high specificity.

Growth is being shaped by the shift from first-generation murine and chimeric antibodies to humanized, fully human, bispecific, antibody-drug conjugate, Fc-engineered, and subcutaneous formulations. Industry adoption is also being reinforced by biosimilar competition, payer demand for value, and continued investment in biologics manufacturing capacity, cold-chain logistics, pharmacovigilance, and real-world evidence generation.

Transformative Shifts in the Monoclonal Antibody Landscape

The monoclonal antibody therapeutics landscape is transforming from a product-by-product innovation cycle into a platform-led ecosystem. Oncology remains a leading field, but immune-mediated diseases, Alzheimer's disease, respiratory syncytial virus prevention, migraine, hypercholesterolemia, and rare diseases demonstrate the broadening clinical utility of antibody-based therapies.

Competitive differentiation is increasingly driven by mechanism of action, route of administration, dosing interval, biomarker strategy, safety profile, and manufacturability. Subcutaneous delivery, longer half-life designs, dual-targeting antibodies, and antibody-drug conjugates are improving patient convenience and clinical outcomes, while biosimilars are reshaping pricing and access in mature therapeutic areas such as oncology and immunology.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across discovery, development, manufacturing, and commercialization of monoclonal antibody therapeutics. AI-enabled protein modeling, antibody sequence optimization, developability screening, and epitope prediction help researchers prioritize candidates with stronger binding profiles, lower aggregation risk, and more favorable manufacturability attributes before costly wet-lab validation.

In clinical development, machine learning supports trial site selection, patient stratification, biomarker discovery, adverse event signal detection, and real-world evidence analysis. In manufacturing, AI-assisted process analytics, predictive maintenance, and digital twins are improving batch consistency, reducing deviations, and supporting quality-by-design practices. The greatest value is emerging where AI is paired with validated biological data, rigorous regulatory documentation, and human scientific oversight.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is gaining strategic importance through expanding biologics manufacturing, rising cancer and autoimmune disease diagnosis, and national policies that encourage biosimilar uptake and domestic innovation. China, India, Japan, South Korea, Australia, and ASEAN markets are becoming more influential across clinical development, contract manufacturing, and commercial expansion, supported by growing clinical trial activity and improving regulatory alignment with international standards.

North America remains a core innovation and commercialization hub, led by the United States with deep venture funding, advanced academic research, FDA regulatory experience, established specialty pharmacy infrastructure, and broad biologics adoption. Canada contributes through clinical research networks and public reimbursement frameworks that increasingly assess cost effectiveness. Latin America is advancing through expanding oncology access, biologics procurement reform, and biosimilar adoption, with Brazil and Mexico serving as central markets for regional commercialization.

Europe benefits from the European Medicines Agency's mature biosimilar pathway, national health technology assessment systems, and strong pharmaceutical manufacturing clusters, making the region highly influential in clinical evidence standards and post-authorization safety monitoring. The Middle East is investing in specialty care infrastructure, oncology centers, and biologics procurement modernization, particularly in GCC countries. Africa remains earlier in adoption, but demand is rising as cancer care capacity, diagnostic access, cold-chain systems, and public-private healthcare investment expand.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are increasingly relevant for monoclonal antibody therapeutics because governments are expanding universal health coverage, oncology services, and biologics procurement, while regulatory reliance pathways and regional cooperation are helping accelerate access. GCC countries are prioritizing specialty care, health system modernization, cancer treatment capacity, and local pharmaceutical capability, creating opportunities for premium biologics, biosimilars, and hospital-based infusion services.

The European Union remains a benchmark for biosimilar policy, pharmacovigilance, centralized regulatory review, and health technology assessment, supporting competition while maintaining strict quality standards. BRICS countries represent a high-priority access frontier due to large patient populations, rising biologics manufacturing capability, expanding clinical trial activity, and government interest in reducing dependence on imported high-cost medicines.

G7 markets continue to shape global standards in clinical evidence, pricing, reimbursement, intellectual property, pharmacovigilance, and biologics quality. NATO-aligned countries, many of which overlap with high-income European and North American markets, are also strengthening supply resilience, domestic biomanufacturing, medicine security, and critical healthcare preparedness after pandemic-era supply disruptions.

Key Country Insights Across Major Monoclonal Antibody Markets

The United States leads global monoclonal antibody commercialization through strong FDA approvals, specialty pharmacy networks, payer management, high clinical trial density, and advanced biomarker-enabled care pathways. Canada emphasizes health technology assessment and provincial reimbursement, while Mexico is expanding specialty medicine access through public and private healthcare channels. Brazil remains Latin America's most significant biologics market, supported by oncology demand, biosimilar adoption, and local production initiatives.

The United Kingdom, Germany, France, Italy, and Spain are major European markets where reimbursement decisions, biosimilar tendering, hospital procurement, and clinical guideline adoption determine uptake. Germany's strong biopharmaceutical base and early market access pathway are influential, while France, Italy, and Spain leverage national procurement and hospital systems to manage biologics spending. Russia has supported domestic biologics production, though market access is affected by geopolitical and supply-chain constraints.

China has become a major force in antibody R&D, clinical trials, biosimilars, and domestic commercialization, supported by regulatory reforms and expanding oncology care. India is a leading biosimilar and biomanufacturing participant with cost-efficient development capabilities and increasing demand for affordable biologics. Japan's market is driven by aging demographics, regulatory quality, and high-value specialty care, while Australia supports advanced clinical research and reimbursement through evidence-based assessment. South Korea is globally recognized for biosimilar manufacturing, contract development, and biologics export strength.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize differentiated antibody platforms with clear clinical value over incremental products in crowded indications. Stronger outcomes can be achieved by aligning target selection, biomarker strategy, patient segmentation, companion diagnostic planning, and health economic evidence early in development.

Organizations should invest in flexible biomanufacturing, high-yield cell line development, continuous processing, analytical characterization, and resilient supply chains to manage demand volatility and quality expectations. Commercial teams should prepare for biosimilar competition through lifecycle management, subcutaneous formulations, patient support services, physician education, and evidence packages that demonstrate real-world effectiveness, safety, and budget impact.

AI adoption should be governed by transparent validation, data lineage, cybersecurity safeguards, model monitoring, and regulatory-ready documentation. Partnerships with academic centers, contract development and manufacturing organizations, diagnostic specialists, healthcare providers, and regional distributors can accelerate global reach while reducing operational, regulatory, and access-related risk.

Research Methodology

This executive summary is developed using a structured secondary research approach anchored in publicly available regulatory, clinical, scientific, and healthcare policy sources. Core inputs include drug approval databases, clinical trial registries, peer-reviewed literature, health authority communications, reimbursement frameworks, pharmacovigilance resources, biosimilar policy documents, and recognized industry publications.

Insights are triangulated across therapeutic area trends, regional policy developments, biologics manufacturing capacity, biosimilar adoption, clinical trial activity, regulatory pathways, and technology shifts such as AI-enabled discovery and process analytics. The methodology emphasizes evidence consistency, source credibility, relevance to monoclonal antibody therapeutics, and exclusion of unsupported claims, market sizing, market share, and forecasting statements.

Conclusion

Monoclonal antibody therapeutics are positioned for continued strategic importance as healthcare systems seek targeted, evidence-based treatments for high-burden diseases. The sector's next phase will be defined by differentiated modalities, biosimilar-driven access, regional manufacturing expansion, and stronger integration of diagnostics, data science, pharmacovigilance, and real-world evidence.

Organizations that combine scientific innovation with scalable manufacturing, payer-aligned value evidence, robust quality systems, and disciplined AI implementation will be best placed to compete. As global demand expands across oncology, immunology, infectious disease prevention, neurology, and rare diseases, leadership will depend on delivering clinically meaningful outcomes while improving affordability, reliability, and patient access.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Monoclonal Antibody Therapeutics Market, by Antibody Type

• 7.1. Chimeric
• 7.2. Fully Human
• 7.3. Humanized
• 7.4. Murine

8. Monoclonal Antibody Therapeutics Market, by Indication

• 8.1. Autoimmune Disorders
  • 8.1.1. Inflammatory Bowel Disease
  • 8.1.2. Multiple Sclerosis
  • 8.1.3. Psoriasis
  • 8.1.4. Rheumatoid Arthritis
• 8.2. Cardiovascular Conditions
• 8.3. Infectious Diseases
  • 8.3.1. Covid-19
  • 8.3.2. HIV
  • 8.3.3. Respiratory Syncytial Virus
• 8.4. Neurological Disorders
  • 8.4.1. Alzheimer's Disease
  • 8.4.2. Multiple Sclerosis
• 8.5. Oncology
  • 8.5.1. Hematological Malignancies
    • 8.5.1.1. Leukemia
    • 8.5.1.2. Multiple Myeloma
    • 8.5.1.3. Non-Hodgkin Lymphoma
  • 8.5.2. Solid Tumors

9. Monoclonal Antibody Therapeutics Market, by Molecular Target

• 9.1. CD20
• 9.2. EGFR
• 9.3. HER2
• 9.4. TNF Alpha

10. Monoclonal Antibody Therapeutics Market, by Production Technology

• 10.1. Hybridoma
• 10.2. Recombinant DNA
• 10.3. Transgenic Animal

11. Monoclonal Antibody Therapeutics Market, by Route Of Administration

• 11.1. Intramuscular
• 11.2. Intravenous
• 11.3. Subcutaneous

12. Monoclonal Antibody Therapeutics Market, by Therapy Type

• 12.1. Combination Therapy
• 12.2. Monotherapy

13. Monoclonal Antibody Therapeutics Market, by End User

• 13.1. Clinics
• 13.2. Diagnostic Laboratories
• 13.3. Hospitals
• 13.4. Specialty Centers

14. Monoclonal Antibody Therapeutics Market, by Distribution Channel

• 14.1. Offline Pharmacy
  • 14.1.1. Hospital Pharmacy
  • 14.1.2. Retail Pharmacy
  • 14.1.3. Specialty Pharmacy
• 14.2. Online Pharmacy

15. Monoclonal Antibody Therapeutics Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Monoclonal Antibody Therapeutics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Monoclonal Antibody Therapeutics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AbbVie Inc.
• 19.2. Amgen Inc.
• 19.3. Astellas Pharma Inc.
• 19.4. Bayer AG
• 19.5. Biogen Inc.
• 19.6. Bristol-Myers Squibb Company
• 19.7. Corvidia Therapeutics Inc. by Novo Nordisk A/S
• 19.8. Eli Lilly and Company
• 19.9. F. Hoffmann-La Roche Ltd
• 19.10. GenScript
• 19.11. Gilead Sciences, Inc
• 19.12. GlaxoSmithKline Plc
• 19.13. Johnson & Johnson
• 19.14. Merck Sharp & Dohme Corp.,
• 19.15. Novartis International AG
• 19.16. Pfizer Inc
• 19.17. Regeneron Pharmaceuticals, Inc.
• 19.18. Sanofi S.A
• 19.19. Takeda Pharmaceutical Company Limited
• 19.20. Teva Pharmaceutical Industries Ltd.